Ravulizumab for Neuromyelitis Optica Spectrum Disorder in Chinese Adults
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosis of NMOSD confirmed by international criteria and positive anti-AQP4 antibody test at screening
- At least one disease relapse (attack) in the past 12 months
- Disability level (EDSS score) of 7 or lower
- Current ability to walk with assistance or independently (EDSS ≤7 means some mobility retained)
- Weighing at least 40 kg (about 88 pounds)
- Meningococcal vaccinations (against serogroups A, C, W, Y, and B where available) completed within the past 3 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called ravulizumab to see if it lowers certain proteins in the blood that may indicate nerve damage in people with NMOSD. If you have NMOSD, this study could help track how well the treatment works.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
Hear when a new NMOSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.